Burgos-Alonso et al.(1414 Burgos-Alonso N, Lobato I, Hernandez I, Sebastian KS, Rodriguez B, March AG, et al. Autologous platelet-rich plasma in the treatment of venous leg ulcers in primary care: a randomised controlled, pilot study. J Wound Care. 2018;27(Sup6):S20-S4. doi: 10.12968/jowc.2018.27.Sup6.S20 https://doi.org/10.12968/jowc.2018.27.Su...
) 2018 Spain |
Pilot Randomized controlled trial with cost -minimization analysis follow-up time (FT) = 9 weeks |
Platelet-Rich Plasma Gel (n = 7) versus Standard treatment (n = 5) |
1b/A |
Moneibet al.(1515 Moneib HA, Youssef SS, Aly DG, Rizk MA, Abdelhakeem YI. Autologous platelet-rich plasma versus conventional therapy for the treatment of chronic venous leg ulcers: A comparative study. J Cosmet Dermatol. 2018;17(3):495-501. doi: 10.1111/jocd.12401 https://doi.org/10.1111/jocd.12401...
) 2018 Egypt |
Case-control FT = 6 weeks |
Platelet-Rich Plasma (n = 20) versus C onventional therapy with vaseline gauze and saline (n = 20) |
3b/B |
Cardeñosaet al.(1616 Cardeñosa ME, Dominguez-Maldonado G, Cordoba-Fernandez A. Efficacy and safety of the use of platelet-rich plasma to manage venous ulcers. J Tissue Viability. 2017;26(2):138-43. doi: 10.1016/j.jtv.2016.11.003 https://doi.org/10.1016/j.jtv.2016.11.00...
) 2017 Spain |
Randomized controlled trial FT = 24 weeks |
Platelet rich in growth factor (n = 55) versus Saline solution (n = 47) |
1b/A |
Somani&Rai(1717 Somani A, Rai R. Comparison of efficacy of Autologous Platelet-rich Fibrin versus Saline Dressing in Chronic Venous Leg Ulcers: a randomised controlled trial. J Cutan Aesthet Surg. 2017;10(1):8-12. doi: 10.4103/JCAS.JCAS_137_16 https://doi.org/10.4103/JCAS.JCAS_137_16...
) 2017 India |
Randomized controlled trial FT = 4 weeks |
Platelet-rich fibrin (n = 9) versus Saline solution (n = 6) |
1b/A |
Senet et al.(1818 Senet P, Bon FX, Benbunan M, Bussel A, Traineau R, Calvo F, et al. Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for chronic venous leg ulcers. J Vasc Surg. 2003;38(6):1342-8. doi: 10.1016/S0741 https://doi.org/10.1016/S0741...
) 2003 France |
Randomized Double-blind Clinical Trial FT = 12 weeks |
Frozen autologous platelets (n = 8) versus Hydrocolloid (n = 7) |
1b/A |
Stacey et al.(1919 Stacey MC, Mata SD, Trengove NJ, Mather CA. Randomised double-blind placebo-controlled trial of topical autologous platelet lysate in venous ulcer healing. Eur J Vasc Endovasc Surg;20(3):296-301. doi: 10.1053/ejvs.2000.1134 https://doi.org/10.1053/ejvs.2000.1134...
) 2000 Australia |
Randomized Double-blind Clinical Trial FT = 9 months |
Platelet lysate (n = 42) Versus Placebo (n = 44) |
|
Pinto et al.(2020 Pinto NR, Ubilla M, Zamora Y, Del Rio V, Dohan Ehrenfest DM, Quirynen M. Leucocyte- and platelet-rich fibrin (L-PRF) as a regenerative medicine strategy for the treatment of refractory leg ulcers: a prospective cohort study. Platelets. 2018;29(5):468-75. doi: 10.1080/09537104.2017.1327654 https://doi.org/10.1080/09537104.2017.13...
) 2018 Chile |
Prospective Cohort FT = 1 year |
Leucocyte- and platelet-rich fibrin (L-PRP) (n = 32) |
2b/B |
Waniczeket al.(2121 Waniczek D, Mikusek W, Kaminski T, Wesecki M, Lorenc Z, Cieslik-Bielecka A. The "biological chamber" method - use of autologous platelet-rich plasma (PRP) in the treatment of poorly healing lower-leg ulcers of venous origin. Pol Przegl Chir. 2015;87(6):283-9. doi: 10.1515/pjs-2015-0055. https://doi.org/10.1515/pjs-2015-0055...
) 2015 Poland |
Case series FT = 10 weeks |
Platelet-Rich Plasma (n = 10) |
4/C |
Kim et al.(2222 Kim SA, Ryu HW, Lee KS, Cho JW. Application of platelet-rich plasma accelerates the wound healing process in acute and chronic ulcers through rapid migration and upregulation of cyclin A and CDK4 in HaCaT cells. Mol Med Rep. 2013;7(2):476-80. doi: 10.3892/mmr.2012.1230 https://doi.org/10.3892/mmr.2012.1230...
) 2013 Republic of Korea |
Case series FT = Not informed
|
Autologous platelet gel or liquid (n = 3) |
4/C |
Park et al.(2323 Park KY, Kim IS, Yeo IK, Kim BJ, Kim MN. Treatment of refractory venous stasis ulcers with autologous platelet-rich plasma and light-emitting diodes: a pilot study. J Dermatolog Treat. 2013;24(5):332-5. doi: 10.3109/09546634.2012.735637 https://doi.org/10.3109/09546634.2012.73...
) 2013 South Korea |
Pilot study FT = 6 weeks |
Platelet-Rich Plasma Gel (n= 16) |
4/C |
Sarvajnamurphyet al.(77 Sarvajnamurthy S, Suryanarayan S, Budamakuntala L, Suresh DH. Autologous platelet rich plasma in chronic venous ulcers: study of 17 cases. J Cutan Aesthet Surg.2013;6(2):97-9. doi: 10.4103/0974-2077.112671 https://doi.org/10.4103/0974-2077.112671...
) 2013 India |
Case series FT = 6 weeks |
Platelet Gel (n = 17) |
4/C |
Leon et al.(2424 Leon JM, Driver VR, Fylling CP, Carter MJ, Anderson C, Wilson J, et al. The clinical relevance of treating chronic wounds with an enhanced near-physiological concentration of platelet-rich plasma gel. Adv Skin Wound Care. 2011;24(8):357-68. doi: 10.1097/01.ASW.0000403249.85131.6f https://doi.org/10.1097/01.ASW.000040324...
) 2011 USA |
Observational study with databases from 39 centers FT = 2.1 weeks |
Platelet-Rich Plasma Gel (Autologel™) (n = 32) |
4/C |
Frykberget al.(2525 Frykberg RG, Driver VR, Carman D, Lucero B, Borris-Hale C, Fylling CP, et al. Chronic wounds treated with a physiologically relevant concentration of platelet-rich plasma gel: a prospective case series. Ostomy Wound Manage [Internet]. 2010 [cited 2018 Aug 08];56(6):36-44. Available from: https://www.o-wm.com/content/chronic-wounds-treated-physiologically-relevant-concentration-platelet-rich-plasma-gel-prosp. https://www.o-wm.com/content/chronic-wou...
) 2010 USA |
Case series FT = 2.8 weeks |
Platelet-Rich Plasma Gel (Autologel™) (n = 16) |
4/C |
O'Connell et al.(2626 O'Connell SM, Impeduglia T, Hessler K, Wang XJ, Carroll RJ, Dardik H. Autologous platelet-rich fibrin matrix as cell therapy in the healing of chronic lower-extremity ulcers. Wound Repair Regen. 2008;16(6):749-56. doi: 10.1111/j.1524-475X.2008.00426.x https://doi.org/10.1111/j.1524-475X.2008...
) 2008 USA |
Pilot study FT = 16 weeks |
Autologous platelet-rich fibrin membrane (PRFM)/ 1 to 3 applications/ (n = 17) Size. 11.2 (0.7-58) |
4/C |
Gürgen, M(2727 Gürgen M. Treatment of chronic wounds with autologous platelet-rich plasma. EWMA Journal [Internet]. 2008 [cited 2018 Aug 08];8(2):5-10. Available from: https://pdfs.semanticscholar.org/b559/e80bee2ad1591847cb514c741a4fee2befa5.pdf
https://pdfs.semanticscholar.org/b559/e8...
) 2008 Norway |
Prospective study FT = 10 months |
Platelet-Rich Plasma (n = 7) |
4/C |